Evidence map›Paper›PMID 29968539›Full record

ArticleCurrent HIV research2018

Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy.

Wei Jiang, Zhenwu Luo, Lisa Martin, Zhuang Wan, Pingfu Fu, Amanda Wagner, Binhua Ling, Sonya L Heath, Azizul Haque, Aimee McRae-Clark

Open access · greenAbstract read
In one paragraph

Article in Current HIV research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wei JiangDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, 29425, United States.
Zhenwu LuoDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, 29425, United States.
Lisa MartinDivison of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, 29425, United States.
Zhuang WanDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, 29425, United States.
Pingfu FuDepartment of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH 44106, United States.
Amanda WagnerDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, 29425, United States.
Binhua LingDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, 70112, United States.
Sonya L HeathDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, United States.
Azizul HaqueDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, 29425, United States.
Aimee McRae-ClarkDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, 29425, United States.
Medical University of South Carolina · USCase Western Reserve University · USTulane University · USUniversity of Alabama at Birmingham · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
NCI NIH HHS R01 CA129560NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI091526NIAID NIH HHS R01 AI093307NIAID NIH HHS R01 AI128864NIAID NIH HHS R24 AI067039NIAID NIH HHS UM1 AI106716NIDA NIH HHS K24 DA038240NIDA NIH HHS U01 DA036935NIH HHS P51 OD011104NINDS NIH HHS R01 NS104016
6 · The paper itself

Abstract

backgroundThe role and mechanism of drug use or abuse in Antiretroviral Therapy (ART)-treated HIV disease are not completely known.

methodsTo investigate the impact of drug use on HIV pathogenesis without confounding by HIV replication and ART adherence, we first analyzed the data from our clinical database in 103 HIV+ subjects with viral-suppressed ART treatment by a multiple regression test.

resultsWe found that HIV+ drug users had lower CD4+ T cell counts but higher CD8+ T cell counts compared to HIV+ non-drug users, and both drug use and nadir CD4+ T cell counts was independently associated with CD4+ T cell recovery after controlling for sex and age. Next, we enrolled individuals from four study groups, HIV-negative and HIV+ subjects without any substance use, HIV-negative and HIV+ subjects with current illicit drug use (either non-injection cocaine or cannabis). All HIV+ subjects were viral-suppressed with ART treatment (≥ 2 years). Notably, HIV+ drug users had increased plasma anti-CD4 IgG levels compared to the other three study groups which were inversely correlated with decreased CD4+ T cell counts only in HIV+ drug users. There was a significant increase in CD4+ T cell recovery following ART in HIV+ non-drug users but not in HIV+ drug users. Anti-CD4 IgGs purified from plasma of HIV+ drug users induced CD4+ T cell death in vitro through Antibody-Dependent Cytotoxicity (ADCC).

conclusionThese results suggest that drug use prevents immune reconstitution in HIV-infected individuals despite long-term ART treatment and viral suppression.

Indexed as

Antibody-Dependent Cell CytotoxicityAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 AntigensCD4 Lymphocyte CountCD4-Positive T-LymphocytesFemaleHIV AntibodiesHIV InfectionsHumansImmunoglobulin GMaleAnti-HIV AgentsCD4 AntigensHIV AntibodiesImmunoglobulin Gantibody-dependent cytotoxicityanti-CD4 IgGantiretroviral therapyCD4+ T cell recoverydrug use.HIV

Identifiers

PMID29968539
PMCPMC6115301
OpenAlexW2886454720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.